Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation.

Autor: Riedell PA; Division of Hematology and Oncology, University of Chicago Medicine, Chicago, IL, USA., Hamadani M; Department of Medicine, CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI, USA.; BMT & Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA., Ahn KW; Department of Medicine, CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI, USA.; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI, USA., Litovich C; Department of Medicine, CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI, USA., Brunstein CG; Department of Medicine, Adult Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA., Cashen AF; Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA., Cohen JB; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA., Epperla N; Division of Hematology, Department of Medicine, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH, USA., Hill BT; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Im A; Division of Hematology/Oncology, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Inwards DJ; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Lister J; Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA., McCarty JM; Bone Marrow Transplant Program, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA., Ravi Kiran Pingali S; Houston Methodist Cancer Center, Houston, TX, USA., Shadman M; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Medical Oncology Division, University of Washington, Seattle, WA, USA., Shaughnessy P; Sarah Cannon Transplant and Cellular Therapy Program Methodist Hospital, San Antonio, TX, USA., Solh M; The Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, GA, USA., Stiff PJ; Department of Medicine, Loyola University Medical Center, Maywood, IL, USA., Vose JM; Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE, USA., Kharfan-Dabaja MA; Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA., Herrera AF; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA., Sauter CS; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA., Smith SM; Section of Hematology/Oncology, The University of Chicago, Chicago, IL, USA.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2021 Dec; Vol. 195 (5), pp. 757-763. Date of Electronic Publication: 2021 Sep 28.
DOI: 10.1111/bjh.17865
Abstrakt: In young and fit patients with mantle cell lymphoma (MCL), intensive induction therapy followed by a consolidative autologous haematopoietic cell transplant (autoHCT) is the standard of care in the front-line setting. Recently, time-to-event analysis has emerged as an important risk assessment tool in lymphoma, though its impact in MCL is not well defined. We utilized the Center for International Blood and Marrow Transplant Research database to evaluate the effect of post-autoHCT time to relapse on overall survival (OS) over time in 461 patients who underwent autoHCT within 12 months of MCL diagnosis. On multivariate analysis, the impact of relapse on OS was greatest at the six-month [hazard ratio (HR) = 7·68], 12-month (HR = 6·68), and 18-month (HR = 5·81) landmark timepoints. Using a dynamic landmark model we demonstrate that adjusted OS at five years following each landmark timepoint improved with time for relapsing and non-relapsing patients. Furthermore, early relapse (<18 months) following autoHCT defines a high-risk group with inferior post-relapse OS. This retrospective analysis highlights the impact of time to relapse on OS in MCL patients undergoing up-front autoHCT and emphasizes the need to consider novel therapeutic approaches for patients suffering early relapse.
(© 2021 British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: